Jincheng Pharmaceutical Unit Gets China License for Good Manufacturing Practice, Production
Shandong Jincheng Pharmaceutical Group (SHE:300233) subsidiary Beijing Jincheng Taier Pharmaceutical obtained a good manufacturing practice compliance certification and production license from the Beijing Drug Administration for its nabumetone dispersible tablets.
Nabumetone is indicated for pain due to rheumatoid arthritis and osteoarthritis.
Price (RMB): ¥11.27, Change: ¥+0.080, Percent Change: +0.71%